NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
27 trialsNCT03180502 2025-07-11
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
Phase 2 Active not recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT00114140 2024-07-08
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02023905 2022-12-29
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Phase 2 Terminated
NCT01478321 2020-03-12
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Phase 2 Terminated
NCT01164189 2019-02-28
TAVAREC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02209428 2019-02-21
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
Huashan Hospital
Phase 2 Unknown
NCT00313729 2019-02-07
Temozolomide in Treating Patients With Low-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT00400816 2018-09-18
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
The Cleveland Clinic
Phase 2 Completed
NCT00619112 2018-01-31
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT00362570 2017-11-30
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00392171 2017-06-07
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01847235 2016-04-26
Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
Seoul National University Hospital
Phase 2 Completed
NCT00498927 2016-02-29
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006263 2015-08-05
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT00003466 2014-07-09
Temozolomide in Treating Patients With Progressive Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00004204 2014-01-06
Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00575887 2013-12-20
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Marmara University
Phase 2 Completed
NCT00360945 2013-09-17
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005955 2013-06-20
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
Duke University
Phase 2 Completed
NCT00004113 2013-06-19
Temozolomide in Treating Patients With Recurrent Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003731 2012-09-24
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00003304 2012-03-06
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00004068 2011-10-04
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00165360 2009-11-02
Prolonged Daily Temozolomide for Low-Grade Glioma
Dana-Farber Cancer Institute
Phase 2 Completed